Evaluation of ⁸⁹Zr-DFO Functionalized Manganese-Iron Oxide Core-Shell Nanoparticles as a HER2-Targeted Multimodal Imaging Candidate Nanoplatform.

Authors

Derya Özel, Ayça Tunçel Oral, Selin Güleç, Fatma Yurt

Published in

ACS omega. Volume 11. Issue 26. Pages 38684-38694. Jul 07, 2026. Epub Jun 22, 2026.

Abstract

Hybrid multimodal imaging agents combining magnetic resonance imaging (MRI) and positron emission tomography (PET) capabilities offer potential for accurate tumor detection and monitoring. In our previous study, we synthesized manganese-loaded, mesoporous silica-coated superparamagnetic iron oxide nanoparticles functionalized with trastuzumab (Fe₃O₄-mSi-NH₂-Mn-Tra), which demonstrated dual T₁/T₂ MRI contrast enhancement and selective cytotoxicity against HER2-positive breast cancer cells in vitro. In the current study, the nanoparticle was labeled with Zirconium-89 (⁸⁹Zr) to evaluate its potential as a HER2-targeted PET imaging agent- candidate. Radiolabeling was performed using the p-isothiocyanatobenzyl-desferrioxamine (p-NCS-Bz-DFO) chelator, ⁸⁹Zr-DFO-Fe₃O₄-mSi-NH₂-Mn-Tra was labeled of 78 ± 2%. The labeled nanoparticles demonstrated high colloidal stability in PBS for up to 24 h and lipophilic (log P = 2.23 ± 0.24). In in vitro uptake studies, radiolabeled nanoparticles showed receptor-specific internalization in HER2-positive SKBR-3 cells (65.25% at 2 h), whereas the uptake was limited in HER2-negative MDA-MB-231 cells (20.22% at 4 h). When the receptor was blocked with trastuzumab, the uptake results was reduced by 11.14 ± 1.2%, confirming HER2-mediated binding. In vivo biodistribution studies in rats have shown that the radiolabeled nanoparticles accumulate in the reticuloendothelial organs (liver 15.53 ± 7.6% ID/g at 120 min) and renal excretion. These results suggest that ⁸⁹Zr-DFO-Fe₃O₄-mSi-NH₂-Mn-Tra nanoparticles may serve as a promising HER2-targeted PET/MRI candidate nanoplatform for further preclinical evaluation.

PMID:
42428894
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.